Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 11—November 2019
Synopsis

Vaccine-Derived Poliovirus Infection among Patients with Primary Immunodeficiency and Effect of Patient Screening on Disease Outcomes, Iran

Mohammadreza Shaghaghi1, Shohreh Shahmahmoodi1, Ali Nili, Hassan Abolhassani, Seyedeh Panid Madani, Ahmad Nejati, Maryam Yousefi, Yaghoob M. Kandelousi, Mona Irannejad, Shiva Shaghaghi, Seyed Mohsen Zahraei, Sussan Mahmoudi, Mohammad Mehdi Gouya, Reza Yazdani, Gholamreza Azizi, Nima Parvaneh, and Asghar AghamohammadiComments to Author 
Author affiliations: Johns Hopkins Hospital, Baltimore, Maryland, USA (M. Shaghaghi); Tehran University of Medical Sciences, Tehran, Iran (M. Shaghaghi, S. Shahmahmoodi, A. Nili, H. Abolhassani, S.P. Madani, A. Nejati, M. Yousefi, Y.M. Kandelousi, M. Irannejad, S. Shaghaghi, R. Yazdani, N. Parvaneh, A. Aghamohammadi); Research Center for Immunodeficiencies, Tehran (M. Shaghaghi, A. Nili, H. Abolhassani, S.P. Madani, M. Irannejad, S. Shaghaghi, R. Yazdani, N. Parvaneh, A. Aghamohammadi); Karolinska University Hospital Huddinge, Stockholm, Sweden (H. Abolhassani); Ministry of Health and Medical Education, Tehran (S.M. Zahraei, S. Mahmoudi, M.M. Gouya); Alborz University of Medical Sciences, Karaj, Iran (G. Azizi); Non-Communicable Diseases Research Center, Karaj (G. Azizi)

Main Article

Table

Patients Age, PID type, and stool screening results in nonparalyzed PID patients in study of vaccine-derived poliovirus infection among patients with PID, Iran, 1995–2018*

Immunodeficiency No. patients (%), N = 266 Age at stool collection, y, median (IQR) Stool screening result
Predominantly antibody deficiencies
AGG 51 (19.17) 5.0 (2.5–10.7) 1 iVDPV, 3 SL, 1 NPEV
CVID 76 (28.57) 12.5 (7.0–20.7) 2 SL, 3 NPEV
HIGM 17 (6.39) 6.8 (3.2–9.5) Negative
HGG
 18 (6.77)
 3.0 (1.2–7.0)
 1 SL
Combined immunodeficiencies
SCID 21 (7.89) 0.9 (0.7–1.2) 5 iVDPVs, 1 SL
Less severe CIDs 21 (7.89) 1.5 (1.0–4.8) 1 iVDPV, 3 SL
CID with syndromic features 20 (7.52) 6.5 (5.0–8.7) Negative
Innate immunity defects 42 (15.79) 4.5 (1.0–5.2) 2 SL

*AGG, agammaglobulinemia; CID, combined immunodeficiency; CVID, common variable immunodeficiency; HGG; unspecified hypogammaglobulinemia; HIGM, hyper-immunoglobulin M syndrome; IQR, interquartile range; iVDPV, immunodeficiency-associated vaccine-derived poliovirus; MHC2, major histocompatibility class 2 deficiency; NPEV, nonpolio enterovirus; PID, primary immunodeficiency; SL, Sabin-like poliovirus; SCID, severe combined immunodeficiency.

Main Article

1These first authors contributed equally to this article.

Page created: October 15, 2019
Page updated: October 15, 2019
Page reviewed: October 15, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external